In a report published by Jefferies, Covidien COV saw FDA Briefing Documents support a positive panel vote and FDA clearance of eV3's PED device.
Jefferies said that PED approval would strengthen COV's positioning in the $1.3B neurovascular market, generating sooner than expected ROIC on last year's eV3 acquisition. “Our new $59 PT blends a $61 P/E-based target, $59 DCF target, and a $58 sum of the parts analysis. Risks include F/X, pricing, utilization, regulatory, and acquisition integration.”
Covidien closed yesterday at $51.09.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.